Kato
OBJECTIVE -- This study characterizes the pharmaceutical treatment of type 2 diabetes from 19891990 to 19961997 in an elderly cohort. RESEARCH DESIGN AND METHODS -- A total of 5, 888 adults aged 65 years were recruited and attended a baseline clinic visit in 19891990 n 5, 201, original cohort ; or 19921993 n 687, African-American [new] cohort ; as participants of the Cardiovascular Health Study. Fasting serum glucose FSG ; was measured at baseline. Medication use was ascertained by drug inventory at all annual clinic visits. Diabetes was defined at baseline as insulin or oral hypoglycemic agent OHA ; use or as having an FSG 7.0 mmol l 126 mg dl ; , the current consensus definition of diabetes. RESULTS -- A total of 387 7% ; original FSG 9.8 mmol l [177 mg dl] ; and 115 17% ; new FSG 10.6 mmol l [191 mg dl] ; cohort members had pharmacologically treated diabetes at baseline. Among those in the original and in the new cohorts who survived follow-up, respectively, OHA use decreased from 80 to 48% P 0.001 ; and from 67 to 50% P 0.003 ; and insulin use increased from 20 to 33% P 0.001 ; and from 33 to 37% P 0.603 ; . There were 396 8% ; original FSG 8.8 mmol l [159 mg dl] ; and 45 7% ; new FSG 10.0 mmol l [181 mg dl] ; cohort members with diabetes untreated at baseline. Among them, respectively, OHA use reached 38 and 30% and insulin use reached 6 and 16% in 19961997. CONCLUSIONS -- Diabetes was common in this elderly cohort, and 80% of treated patients with diabetes at baseline were not achieving fasting glucose goals of 6.7 mmol l 120 mg dl ; . Many untreated at baseline remained untreated after 7 years of follow-up. Diabetes Care 22: 736742, 1999.
Kato 20-220
Donna kato give my love to calvin, oscelyn.
Recently Published Abstracts Effects of ipriflavone on bone loss following a bilateral ovariectomy and menopause: a randomized placebo-controlled study. Katase K, Kato T, Hirai Y, et al. Calcif Tissue Int 2001; 69: 73-77.
57. Sharma D. Carcinoma of oesophagus--aetiological factors and epidemiology: an overview. J Indian Med Assoc 1999; 97 9 ; : 360364. 58. Terry PD, Lagergren J, Wolk A, Steineck G, Nyren O. Dietary intake of heterocyclic amines and cancers of the esophagus and gastric cardia. Cancer Epidemiol Biomark Prev 2003; 12 9 ; : 940-944. 59. Bogen KT, Keating GA. U.S. dietary exposures to heterocyclic amines. J Exposure Anal Environ Epidemiol 2001; 11 3 ; : 155-168. 60. Zhang J, Schulz WA, Li Y, Wang R, Zotz R, Wen D, Siegel D, Ross D, Gabbert HE, Sarbia M. Association of NAD P ; H: quinone oxidoreductase 1 NQO1 ; C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. Carcinogenesis 2003; 24 5 ; : 905-909. 61. Hamajima N, Matsuo K, Iwata H, Shinoda M, Yamamura Y, Kato T, Hatooka S, Mitsudomi T, Suyama M, Kagami Y, Ogura M, Ando M, Sugimura Y, Tajima K. NAD P ; H: quinone oxidoreductase 1 NQO1 ; C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol 2002; 7 2 ; : 103-108. 62. Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, Vaughan TL, Farrow DC, Schoenberg JB, Stanford JL, Ahsan H, West AB, Rotterdam H, Blot WJ, Fraumeni JF, Jr. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 2001; 10 ; : 1055-1062. 63. Song C, Xing D, Tan W, Wei Q, Lin D. Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res 2001; 61 8 ; : 3272-3275. 64. Wu DC, Wu IC, Lee JM, Hsu HK, Kao EL, Chou SH, Wu MT. Helicobacter pylori infection: a protective factor for esophageal squamous cell carcinoma in a Taiwanese population. J Gastroenterol 2005; 100 3 ; : 588-593. 65. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB, West AB, Rotterdam H, Fraumeni JF, Jr., Blot WJ. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998; 7 2 ; : 97-102. 66. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin NSAIDs and esophageal cancer: a systematic review and meta-analysis.[see comment]. [Review] [85 refs]. Gastroenterology 2003; 124 1 ; : 47-56. 67. Ghadirian P. Thermal irritation and esophageal cancer in northern Iran. Cancer 1987; 60: 1909-1914. Zaridze D, Blettner M, Trapeznikou N, Kuvshinou J, Matiakin E, Poljakov B. Survey of a population with a high incidence of oral and oesophageal cancer. Int J Cancer 1985; 36: 153-158. Zaridze DG, Huvshinov JP, Matiakin E, Polakov BI, Boyle P, Blettner M. Chemoprevention of oral and esophageal cancer in Uzbekistan, Union of Soviet Socialist Republics. J Natl Cancer Inst Monogr 1985; 69: 259-262. Victora CG, Munoz N, Day NE, Barcelos LB, Peccin DA, Braga NM. Hot beverages and oesophageal cancer in southern Brazil: a case-control study. Int J Cancer 1987; 39 6 ; : 710-716. 71. Castellsague X, Munoz N, De Stefani E, Victora CG, Castelletto R, Rolon PA. Influence of mate drinking, hot beverages and diet on esophageal cancer risk in South America. Int J Cancer 2000; 88: 658-664. Launoy G, Milan C, Day NE, Faivre J, Pienkowski P, Gignoux M. Oesophageal cancer in France: potential importance of hot alcoholic drinks. Int J Cancer 1997; 71 6 ; : 917923. 73. Wijnhoven BP, Tilanus HW, Dinjens WN. Molecular biology of Barrett's adenocarcinoma. Ann Surg 2001; 233: 322-337. Chow WH, Blaser MJ, Blot WJ, Gammon MD, Vaughan TL, Risch HA, Perez-Perez GI, Schoenberg JB, Stanford JL, Rotterdam H, West AB, Fraumeni JF, Jr. An inverse relation between cagA + strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998; 58 4 ; : 588-590. 75. Dellon ES, Shaheen NJ. Does Screening for Barrett's Esophagus and Adenocarcinoma of the Esophagus Prolong Survival? J Clin Oncol 2005; 23 20 ; : 4478-4482. 76. Lambert R, Hainaut P, Parkin DM. Premalignant lesions of the esophagogastric mucosa. Semin Oncol 2004; 31 4 ; : 498-512. 77. Lambert R. Diagnosis of esophagogastric tumors. Endoscopy 2004; 36 2 ; : 110-119. 78. Sharma P, McQuaid K, Dent J, Fennerty MB, Sampliner R, Spechler S, Cameron A, Corley D, Falk G, Goldblum J, Hunter J, Jankowski J, Lundell L, Reid B, Shaheen NJ, Sonnenberg A, Wang K, Weinstein W, Workshop AGAC. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterol 2004; 127 1 ; : 310-330. 79. Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. J Gastroenterol 2002; 97 8 ; : 1888-1895. 80. Perdue DG, Murray J, Wang KK. The wizards of odds: cost-effectiveness, Barrett's screening, and surveillance guidelines.[comment]. Clin Gastroenterol Hepatol 2004; 2 10 ; : 865-867. 81. Dimick JB, Pronovost PJ, Cowan JA, Lipsett PA. Surgical volume and quality of care for esophageal resection: do high-volume hospitals have fewer complications? Ann Thorac Surg 2003; 75 2 ; : 337-341. 82. Dimick JB, Wainess RM, Upchurch GR, Jr., Iannettoni MD, Orringer MB. National trends in outcomes for esophageal resection. Ann Thorac Surg 2005; 79 1 ; : 212-216. 83. Swisher SG, Deford L, Merriman KW, Walsh GL, Smythe R, Vaporicyan A, Ajani JA, Brown T, Komaki R, Roth JA, Putnam JB. Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardio Surg 2000; 119 6 ; : 1126-1132. 84. Hebert JR, Miller DR. Methodologic considerations for investigating the diet-cancer link. J Clin Nutr 1988; 47: 1068-1077. n.
Infiltration into the conjunctiva by clodronate liposomes in experimental immune-mediated blepharoconjunctivitis. Cell Biol Int 2005; 29 4 ; : 277-286 VUmc ; 294. Furukawa T, Klppel G, Adsay NV, AlboresSaavedra J, Fukushima N, Horii A, Hruban RH, Kato Y, Klimstra DS, Longnecker DS, Lttges J, Offerhaus GJA, Shimizu M, Sunamura M, Suriawinata A, Takaori K, Yonezawa S. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch 2005; 447 5 ; : 794-799 AMC ; 295. Galardy PJ, Ploegh HL, Ovaa H. Mechanismbased proteomics tools based on ubiquitin and ubiquitin-like proteins: crystallography, activity profiling, and protease identification. Methods Enzymol 2005; 399: 120-31 NKI ; 296. Garcia Vallejo JJ, van Dijk W, van Die I, Gringhuis SI. Tumor necrosis factor-alpha upregulates the expression of beta1, 4galactosyltransferase I in primary human endothelial cells by mRNA stabilization. J Biol Chem 2005; 280 13 ; : 12676-12682 VUmc ; 297. Garcia-Gonzalez MA, Lanas A, Wu J, Benito R, Santolaria S, Cuijpers JP, Pena AS. Lack of association of IL-12 p40 gene polymorphism with peptic ulcer disease. Hum Immunol 2005; 66 1 ; : 72-76 VUmc ; 298. Garcia-Gonzalez MA, Savelkoul PH, Benito R, Santolaria S, Crusius JB, Pena AS, Lanas A. No allelic variant associations of the IL-1 and TNF gene polymorphisms in the susceptibility to duodenal ulcer disease. Int J Immunogenet 2005; 32 5 ; : 299306 VUmc ; 299. Garzon MR, Berraondo P, Crettaz J, Ochoa L, Vera M, Lasarte JJ, Vales A, van Rooijen N, Ruiz J, Prieto J, Zulueta J, Gonzalez-Aseguinolaza G. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex. Vaccine 2005; 23 11 ; : 1384-1392 VUmc ; 300. Geerts D, Revet IM, Jorritsma G, Schilderink N, Versteeg R. MEIS homeobox genes in neuroblastoma. Cancer Lett 2005; 228 1-2 ; : 43-50 AMC ; 301. Geier A, Zollner G, Dietrich CG, Wagner M, Fickert P, Denk H, van Rooijen N, Matern S, Gartung C, Trauner M. Cytokine-independent repression of rodent Ntcp in obstructive cholestasis. Hepatology 2005; 41 3 ; : 470-477 VUmc ; 302. Geiger TR, Peeper DS. The neurotrophic receptor TrkB in anoikis resistance and metastasis: a perspective. Cancer Res 2005; 65: 7033-6 NKI ; 303. Genest PA, ter Riet B, Dumas C, Papadopoulou B, Van Luenen HG, Borst P. Formation of linear inverted repeat amplicons following targeting of an essential gene in Leishmania. Nucleic Acids Res 2005; 33: 1699-709 NKI.
JPET #111377 trend was observed in the Vss with increasing dose. The estimated Km value 67.28 mIU ml ; is almost the same as the SC50 of rHuEPO, suggesting that the receptor-binding is closely related to the saturable elimination of the drug i.e., receptor-mediated drug elimination ; Veng-Pedersen et al., 1999 ; . The prolonged plasma concentrations after SC dosing and slow absorption indicate flip-flop kinetics. The estimated F 58.6% ; is in good agreement with the previously determined values of 43~62% via non-compartmental analysis after SC administration Kato et al., 2001 ; . No study has previously examined dose-dependent F of SC rHuEPO in rats. Although dose-dependent F for SC dosing was tested and ranged from 0.56~0.61, it was not considered significant and instead, estimated as a single parameter in the final fitting. Pharmacodynamics. Owing to the limit of quantification of the assay it was assumed that the endogenous EPO is zero in rat plasma. Prior to rHuEPO administration EPO receptors are partially occupied by the endogenous EPO that is responsible for maintaining the baseline levels of erythrocytes. The erythropoietic activity of the endogenous EPO in the system is factored into the estimation of the production rate kin ; since it is obtained from the baseline and cell lifespan. Moreover, the concentration of rHuEPO exogenously given is significantly larger than endogenous levels in rats. Therefore, any influence of the endogenous level in the current model on the estimation of parameters can be considered to be minimal. Models that describe PD functional adaptation processes have been introduced based on their primary mechanism Mager et al., 2003 ; . For the tolerance phenomenon observed in our data, two possible mechanisms relevant to erythropoietic regulation can and kava.
11 months ago source s ; : mother tongue 0% 0 votes 0 rating: good answer 0 rating: bad answer report it by jgidd member since: march 28, 2007 total points: 325 level 2 ; add to my contacts block user in bulgarian the word kato or means like.
Kato 8017
GJ, Foster DC: Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369: 565, 1994 Wendling F, Maraskovsky E, Debill N, Florindo C, Teepe M, Titeux M, Methia N, Breton-Gorlus J, Cosman D, Vainchenker W: c-Mpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 369: 571, 1994 Kato T, Ogami K, Shimada Y, Iwamatsu A, Sohma Y, Akahori H, Kokubo A, Kudo Y, Maeda E, Kobayashi K, Ohashi H, Ozawa T, Inoue H, Kawamura K, Miyazaki H: Purification and characterization of thrombopoietin. J Biochem 118: 229, 1995 Banu N, Wang JF, Deng B, Groopman JE, Avraham H: Modulation of megakaryocytopoiesis by thrombopoietin: The c-Mpl ligand. Blood 86: 1331, 1995 Debili N, Wendling F, Katz A, Guichard J, Breton-Gorius J, Hunt P, Vainchenker W: The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. Blood 86: 2516, 1995 Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Baily MC, Forstrom JW, Buddle MM, Oort PJ, Hagen FS, Roth GJ, Papayannopoulou T, Foster DC: Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 369: 568, 1994 Kaushansky K: Thrombopoietin: The primary regulator of platelet production. Blood 86: 419, 1995 Kaushansky K, Broudy VC, Lin N, Jorgensen MJ, McCarty J, Fox N, Zucker-Franklin D, Lofton-Day C: Thrombopoietin, the Mpl ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci USA 92: 3234, 1995 Zeigler FC, Sauvage Fd, Widmer HR, Keller GA, Donahue C, Schreiber RD, Malloy B, Hass P, Eaton D, Matthews W: In vitro megakaryopoietic and thrombopoietic activity of c-mpl ligand TPO ; on purified murine hematopoietic stem cells. Blood 84: 4045, 1994 McCarty JM, Sprugel KH, Fox NE, Sabath DE, Kaushansky K: Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 86: 3668, 1995 Stoffel R, Wiestner A, Skoda RC: Thrombopoietin in thrombocytopenic mice: Evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 87: 567, 1996 Broudy VC, Lin NL, Kaushansky K: Thrombopoietin c-mpl ligand ; acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 85: 1719, 1995 Emerson SG, Yang Y-C, Clark SC, Long MW: Human recombinant granulocyte-macrophage colony stimulating factor and interleukin 3 have overlapping but distinct hematopoietic activities. J Clin Invest 76: 1286, 1988 Donahue RE, Yang Y-C, Clark SC: Human P40 T-cell growth factor interleukin-9 ; supports erythroid colony formation. Blood 755: 2271, 1990 Migliaccio AR, Bruno M, Migliaccio G: Evidence for direct action human biosynthetic recombinant ; GM-CSF on erythroid progenitors in serum-free culture. Blood 70: 1867, 1987 Migliaccio G, Migliaccio AR, Valinsky J, Langley K, Zsebo K, Visser JWM, Adamson JW: Stem cell factor induces proliferation and differentiation of highly enriched murine hematopoietic cells. Proc Natl Acad Sci USA 88: 7420, 1991 Sonoda Y, Yang Y-C, Clark SC, Long MW: Erythroid burstpromoting activity of purified recombinant human GM-CSF and interleukin-3: Studies with anti-GM-CSF and anti-IL-3 sera and studies in serum-free cultures. Blood 72: 1381, 1988 Lin C-S, Lim S-K, D'Agati V, Costantini F: Differential ef and kenalog.
Kato japanese cuisine
Adjusted percentages controlling for poverty and education. 167 Source: The Commonwealth Fund 2001 Health Care Quality Survey.
Kato ai
The first comes right after the scene, where denny, kato and mirana is watching over aniki and is a 52 second long els of the shoreline where kato and moose are playing ball, with ken and mo watching and keppra.
12 visits for same condition, same service requires PA for entire episode of care including bi-lateral treatment ; , provided visit limit does not apply. Only initial 12 visits do not require Prior Authorization. Physician Orders include services ordered by the member's PCP and or a specialist, provided benefit allows for self-referral or PCP referred member for evaluation and treatment. PCP Orders should include both visit and length of authorization parameters and should be in writing. If verbal orders are given, a note should be included in the patient's medical chart. Coverage is dependent upon medical necessity, eligibility, contract limitations and exclusions. 2007 BH Benefit Grid FINAL VERSION - 16.
IC50 values were determined by regression linear and expressed as means SD of tree replicates. b Quercetin was used as positive control Kato et al., 2003 ; Regasini, et al, Phytochemistry, 2007 in press and ketek.
1: 20PM OK.00006 Theoretical Analysis of Critical Marangoni Number for Oscillatory Flows with High Prandtl Number Fluids , SHINICHI YODA, SATOSHI MATSUMOTO, Japan Aerospace Exploration Agency, ATSUKI KOMIYA.
23. Chen C, Okayama H 1987 High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7: 27452752 24. Meyer ME, Pornon A, Ji JW, Bocquel MT, Chambon P, Gronemeyer H 1990 Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor. EMBO J 9: 39233932 25. Takimoto GS, Tasset DM, Eppert AC, Horwitz KB 1992 Hormone-induced progesterone receptor phosphorylation consists of sequential DNA-independent and DNAdependent stages: analysis with zinc finger mutants and the progesterone antagonist ZK98299. Proc Natl Acad Sci USA 89: 30503054 26. de Wet JR, Wood KV, DeLuca M, Helinski DR, Subramani S 1987 Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol 7: 725737 27. Cato AC, Miksicek R, Schutz G, Arnemann J, Beato M 1986 The hormone regulatory element of mouse mammary tumour virus mediates progesterone induction. EMBO J 5: 22372240 28. Gorman CM, Merlino GT, Willingham MC, Pastan I, Howard BH The 1982 Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. Proc Natl Acad Sci USA 79: 67776781 29. McGrory WJ, Bautista DS, Graham FL 1988 A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 163: 614617 30. Gluzman Y, Herwig R, Solnick D 1982 Helper-free adenovirus type-5 vectors. In: Gluzaman Y ed ; Eukaryotic Viral Vectors. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp 187192 31. Alcorn JL, Gao E, Chen Q, Smith ME, Gerard RD, Mendelson CR 1993 Genomic elements involved in transcriptional regulation of the rabbit surfactant protein-A gene. Mol Endocrinol 7: 10721085 32. Clarke CL, Zano RJ, Mortel R, Satyaswaroop PG 1987 Monoclonal antibodies to human progesterone receptor: characterization by biochemical and immunohistochemical techniques. Endocrinology 121: 11231132 and ketoprofen.
Kato member last activity: 20th march 2006 join date: 20th march 2006 posts total 0 0 posts per day ; private message: send a private message to kato name : kato location research institute : spb state university study occupation : 4 research interests : oceanology kato is not a member of any public groups all times are gmt.
Migraine prevalence is approximately 12%, with women being affected at approximately three times the rate of men 18% vs 6% ; .1 Of these women, around 50% report migraine with menstruation.2 Menstrual migraine MM ; is defined by start of the headache on day 2 to day + 3 of menses with no day 0 ; .3 and kineret.
Kato ballroom events
John country: usa 212 steve jansen posted - 02 19 2008 : : 13 yes kato is mostly n scale and of that mostly outside of the usa maybe and kato.
Based on 40 years of clinical use in Europe and recent scientific studies, Shaklee scientists have formulated this absolutely unique combination. PhytoFem is a natural, concentrated source of phytoestrogens from various plants and herbs proven to help regulate hormonal balance in women during the transitional period of menopause. * Shaklee PhytoFem contains the well-researched herb, Black Cohosh, that helps regulate hormonal balance in women during the transitional period of menopause * along with phytoestrogens from Soy and Flaxseed. Similar in structure to human estrogen, Soy isoflavones and flaxseed lignans can bind to estrogen receptors, thereby exerting an estrogen-like effect. * PhytoFem also provides phytoestrogens from Dong Quai, Red Clover, and Licorice and klonopin.
NVP levels ? 16% Use EFV standard dose ? RFB 450-600mg QD or 600mg 3x weekly RFB levels ? 16% No LPV r dose adjustment ? RFB to 150mg every other day RFB levels? 3x Use NFV 1250mg BID ? RFB to 150mg QD or 300mg 3x week NFV levels? 32% if given 750mg TID instead of 1250 BID. ? IDV to 1000mg TID ? RFB to 150mg QD or 300mg 3x week IDV levels ? 32% while RFB levels increase 2X. Not commonly used as sole PI. Refer to individual drugs for boosted PI recommendations. Must use SAQ RIT std doses ; ? RFB to 150mg QD or 3x week.
Effect of age on the characteristics and clinical behavior of non- Hodgkin's lymphoma patients. The NonHodgkin's Lymphoma Classification Project. Ann Oncol 1997; 8 10 ; : 973-8. Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92 9 ; : 3152-62. Akasaka T, Akasaka H, Ueda C, Yonetani N, Maesako Y, Shimizu A, et al. Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC immunoglobulin heavy-chain fusion gene. J Clin Oncol 2000; 18 3 ; : 510-18. van Krieken JH, Raffeld M, Raghoebier S, Jaffe ES, van Ommen GJ, Kluin PM. Molecular genetics of gastrointestinal non-Hodgkin's lymphomas: unusual prevalence and pattern of c-myc rearrangements in aggressive lymphomas. Blood 1990; 76 4 ; : 797-800. Weiss LM, Warnke RA, Sklar J, Cleary ML. Molecular analysis of the t 14; 18 ; chromosomal translocation in malignant lymphomas. N Engl J Med 1987; 317 19 ; : 1185-9. Hill ME, MacLennan KA, Cunningham DC, Vaughan Hudson B, Burke M, Clarke P, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood 1996; 88 3 ; : 1046-51. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive nonHodgkin's lymphoma. Blood 1997; 90 1 ; : 244-51. Piris MA, Pezzella F, Martinez-Montero JC, Orradre JL, Villuendas R, Sanchez-Beato M, et al. p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 1994; 69 2 ; : 337-41. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte GELA ; . Blood 1996; 87 1 ; : 265-72. Kramer MH, Hermans J, Parker J, Krol AD, Kluin-Nelemans JC, Haak HL, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1996; 14 7 ; : 2131-8. Tang SC, Visser L, Hepperle B, Hanson J, Poppema S. Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases. J Clin Oncol 1994; 12 1 ; : 149-54. Barrans SL, Carter I, Owen RG, Davies FE, Patmore RD, Haynes AP, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99 4 ; : 1136-43. Koduru PR, Raju K, Vadmal V, Menezes G, Shah S, Susin M, et al. Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood 1997; 90 10 ; : 4078-91. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997; 337 8 ; : 529-34. Leroy K, Haioun C, Lepage E, Le Metayer N, Berger F, Labouyrie E, et al. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 2002; 13 7 ; : 1108-15 and kytril.
Discount generic Kato
Roseola low temperature, palliation treatment, vesicular diseases, ichthyosis vulgaris skin condition and transudate and ascites. Ru 486 availability, lumbar radiculopathy and chiropractic, urinary urgency home remedies and age to start sleep training or sigmoid disease.
Kato orient express
Kzto, kat9, kat, katk, kao, kaato, katp, mato, kaho, kayo, lato, kago, katoo, ka5o, akto, kkato, oato.
Kato 10 382
Kato 20-220, kato 8017, kato japanese cuisine, kato ai and kato ballroom events. Discount generic kato, kato orient express, kato 10 382 and kato origin or kato family.
|
